Evaluation of the clinical efficacy of flutiform®(fluticasone propionate /formoterol fumarate) on severe persistent bronchial asthma

Not Applicable

• Conditions: Bronchial asthma

• Registration Number: JPRN-UMIN000016856
• Lead Sponsor: Dokkyo Medical University Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-03-20
• Study Completion: 2016-01-05
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Not provided

Exclusion Criteria

(1)Patients with COPD (2)Patients who take SABA other than treatment of exacerbations (3)Patients who had a history of adverse reaction to ICS or LABA (4)Patients who took flutiform ® within four weeks (5)Patients with severe cardiac, hepatic, renal, pulmonary, or hematologic disease (6)Current malignancy (7)Smoking within past 1 year (8)Those who are pregnant, under-lactation, or desire pregnancy (9)Unsuitability as determined by the investigator

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Asthma control questionnaire (ACQ)

Secondary Outcome Measures

Name	Time	Method
Pulmonary function tests (FEV1, %FEV1, FEV1%, V25, V50), FeNO, IOS indices (R5, R20, R5-R20, X5, Ax), the number of times rescue medications are used (oral steroids, infusion (steroids/aminophylline), SABA)